Tethra Biosciences Inc.
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations. Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups: Group 1: Bladder cancer Group 2: Breast cancer: Triple-negative breast cancer (TNBC) Group 3: Lung cancer (non-small cell lung cancer \[NSCLC\] and small cell lung cancer \[SCLC\])…
Inclusion Criteria: 1. Males or females aged ≥ 18 years. 2. Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists 1. For Phase 1, all tumor types may be enrolled 2. For Phase 2, subjects will be enrolled as per the study design section above 3. ECOG performance status of 0-2. 4. Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-ver…
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.